🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

163 results for “Ark” Clear

  1. An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

    Pharma Mar S.A.

    Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis

    phase 1 other active

    1 trial

  2. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects und

    Pharma Mar S.A.

    Epilepsy

    phase 1 other active

    1 trial

  3. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Elvanse (lisdexamfetamine dimesylate) 70 mg hard capsules, Marketing Authorization Holder: Takeda Pharmaceuticals International AG Ireland Branch, Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, D02 HW68, Ireland, in healthy adult, human subjects under fas

    Pharma Mar S.A.

    ADHD

    phase 1 other active

    1 trial

  4. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

    Pharma Mar S.A.

    Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis

    phase 1 other active

    1 trial

  5. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.

    Pharma Mar S.A.

    Axial spondyloarthritis, Crohn’s disease, Ulcerative colitis, Atopic dermatitis, Rheumatoid arthritis, Psoriatic arthritis

    phase 1 other active

    1 trial

  6. Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroids

    Cassiopea S.p.A.

    Test of vasocontriction properties for classification of topical steroid potency

    phase 1 other active

    1 trial

  7. BIIB094

    IONIS PHARMACEUTICALS INC

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  8. Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

    Orion

    Parkinson disease

    phase 1 other active

    1 trial

  9. Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

    Orion

    Parkinson desease

    phase 1 other active

    1 trial

  10. CE marked Philips Motiva system

    United Therapeutics Europe Ltd

    COPD

    phase 1 other completed

    1 trial

  11. CERE-120: AAV2-NTN

    SANGAMO THERAPEUTICS, INC

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  12. DNL201

    Denali Therapeutics

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  13. First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

    Pharma Mar S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

  14. GRoningen Early-PD Ambroxol Treatment Pharmacokinetics

    Disc Medicine

    Parkinson's disease

    phase 1 other active

    1 trial

  15. GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  16. HEC122505MsOH

    Sunshine Biopharma

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  17. HER-2/neu peptide vaccine

    Marker Therapeutics

    HER2-positive Breast Cancer

    phase 1 mab completed

    1 trial

  18. Human Amniotic Epithelial Stem Cells

    China SXT Pharmaceuticals

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  19. IRX4204

    IO Biotech

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  20. Infudopa i.v.

    Lxo Ireland Designated Activity Company

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  21. Levodopa

    Black Diamond Therapeutics

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  22. Levodopa Cyclops®

    BRIGHT MINDS BIOSCIENCES INC.

    Parkinson

    phase 1 other completed

    1 trial

  23. Lu AF28996 in Patients With Parkinson's Disease

    H. Lundbeck A/S

    Parkinson's Disease

    phase 1 other active

    1 trial

  24. MEDI1341

    Takeda Pharmaceuticals International AG

    Parkinson's Disease

    phase 1 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources